NASDAQ:PRTK Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis → Will this AI Micro-Cap be Bigger than NVIDIA? (From Behind the Markets) (Ad) Free PRTK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.19▼$2.2450-Day Range$2.17▼$2.2352-Week Range$1.29▼$3.65Volume4.76 million shsAverage Volume724,253 shsMarket Capitalization$127.82 millionP/E RatioN/ADividend YieldN/APrice Target$2.15 Stock AnalysisStock Analysis Get Paratek Pharmaceuticals alerts: Email Address Paratek Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside3.6% Downside$2.15 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.98Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.02 out of 5 starsMedical Sector913th out of 913 stocksBiotechnology Industry10th out of 10 stocks 1.0 Analyst's Opinion Consensus RatingParatek Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageParatek Pharmaceuticals has received no research coverage in the past 90 days.Read more about Paratek Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PRTK. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreParatek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.Environmental SustainabilityThe Environmental Impact score for Paratek Pharmaceuticals is -2.98. Previous Next N/A News and Social Media Coverage Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Paratek Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About Paratek Pharmaceuticals Stock (NASDAQ:PRTK)Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.Read More Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> PRTK Stock News HeadlinesMarch 5, 2024 | markets.businessinsider.comParatek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPsFebruary 24, 2024 | benzinga.comMira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and DatesOctober 5, 2023 | finance.yahoo.comParatek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023September 21, 2023 | finance.yahoo.comNovo Holdings closes $462 mln acquisition of Paratek PharmaceuticalsSeptember 21, 2023 | finance.yahoo.comGurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.September 19, 2023 | finance.yahoo.comParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the companySeptember 18, 2023 | bizjournals.comParatek Pharmaceuticals shareholders approve $462M buyout dealSeptember 18, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 12, 2023 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 7, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsAugust 10, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTKAugust 7, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Paratek Pharmaceuticals (PRTK)August 4, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) ForecastsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionJuly 27, 2023 | seekingalpha.comPRTK Paratek Pharmaceuticals, Inc.July 11, 2023 | finance.yahoo.comNexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalJuly 11, 2023 | msn.comHC Wainwright & Co. Reiterates Paratek Pharmaceuticals (PRTK) Neutral RecommendationJuly 10, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Paratek Pharmaceuticals (PRTK)July 10, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxJuly 6, 2023 | msn.comParatek Pharmaceuticals (PRTK) Price Target Decreased by 41.87% to 3.16June 27, 2023 | msn.comParatek antibiotic Nuzyra to receive EU orphan drug statusJune 27, 2023 | msn.comParatek investor NexPoint warns it may vote against takeover dealJune 27, 2023 | finance.yahoo.comParatek Pharmaceuticals Acknowledges Receipt of NexPoint LetterJune 27, 2023 | finance.yahoo.comNexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalSee More Headlines Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees268Year Founded1996Price Target and Rating Average Stock Price Target$2.15 High Stock Price Target$2.15 Low Stock Price Target$2.15 Potential Upside/Downside-3.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,570,000.00 Net Margins-35.44% Pretax Margin-35.35% Return on EquityN/A Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.46 Sales & Book Value Annual Sales$160.27 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.08) per share Price / Book-0.72Miscellaneous Outstanding Shares57,320,000Free Float52,736,000Market Cap$127.82 million OptionableOptionable Beta1.70 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael F. Bigham CPA (Age 65)CPA, M.B.A., MBA, Exec. Chairman Comp: $954.39kDr. Evan Loh FACC (Age 64)FAHA, M.D., CEO & Director Comp: $1.14MMr. Adam Woodrow (Age 56)Pres & Chief Commercial Officer Comp: $763.51kMs. Sarah Higgins (Age 48)VP of Fin., Controller & Principal Accounting Officer Mr. William M. Haskel (Age 61)Sr. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. Mr. Jonathan LightDeputy Gen. Counsel & Chief Compliance OfficerMs. Karen McGrathChief People OfficerMr. Randall B. Brenner (Age 50)Chief Devel. & Regulatory Officer More ExecutivesKey CompetitorsHookipa PharmaNASDAQ:HOOKKezar Life SciencesNASDAQ:KZRNextCureNASDAQ:NXTCNektar TherapeuticsNASDAQ:NKTROmerosNASDAQ:OMERView All CompetitorsInsidersMichael BighamSold 31,250 sharesTotal: $68,750.00 ($2.20/share)Evan LohSold 48,967 sharesTotal: $107,727.40 ($2.20/share)William M HaskelSold 34,526 sharesTotal: $75,957.20 ($2.20/share)Randall B BrennerSold 27,603 sharesTotal: $60,726.60 ($2.20/share) PRTK Stock Analysis - Frequently Asked Questions Should I buy or sell Paratek Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares. View PRTK analyst ratings or view top-rated stocks. What is Paratek Pharmaceuticals' stock price target for 2024? 1 Wall Street research analysts have issued 1-year target prices for Paratek Pharmaceuticals' stock. Their PRTK share price targets range from $2.15 to $2.15. On average, they predict the company's share price to reach $2.15 in the next year. This suggests that the stock has a possible downside of 3.6%. View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its quarterly earnings data on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to the consensus estimate of $22.98 million. During the same quarter in the previous year, the firm posted ($0.46) EPS. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL). This page (NASDAQ:PRTK) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Paratek Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.